Guardant Access
is committed to making Shield™
accessible to all eligible patients
accessible to all eligible patients
For US Patients
- Designed to limit surprise bills by notifying patients with an estimated out-of-pocket cost >$50 USD
- Eligible patients can receive financial assistance
For US Practices
- We provide Shield-related eligibility confirmation, manage claims and appeals, and field all your patients’ billing questions
Financial assistance eligibility determination is available
for all eligible patients regardless of insurance type
Sign up to receive the latest updates on ShieldTM
Shield™ is a qualitative laboratory developed test intended to detect colorectal cancer by identifying genomic and epigenomic alterations in cell-free DNA in plasma from blood collected in Guardant blood collection tubes.
- The assay is intended to be complementary to and not a replacement for current recommended colorectal cancer screening methods
- Patients with an "abnormal signal detected" Shield test result should be referred for colonoscopic evaluation
- A "normal signal detected" Shield test result does not preclude the presence of colorectal cancer, and patients should continue participating in guideline-recommended screening programs
- Shield was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing. This test has not been cleared or approved by the US FDA
